Skip to content

World Bleeding Disorders Registry

World Bleeding Disorders Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03327779
Acronym
WBDR
Enrollment
20000
Registered
2017-10-31
Start date
2018-01-26
Completion date
2028-01-31
Last updated
2023-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A, Hemophilia B, Von Willebrand Diseases

Brief summary

The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient data and guide clinical practice. With informed consent from the patient, the WBDR stores anonymous data about the person's disease, such as hemophilia type and severity, symptoms, and treatment.

Detailed description

The WBDR is a prospective, global registry of patients diagnosed with hemophilia A and B. Following the success of a pilot study, implementation of the full scale WBDR is underway. The goals are to enroll at least 200 HTCs from more than 50 countries, and at least 10,000 people with hemophilia, during the first five years, aiming for representation of patients from around the world and from all levels of access to care. Minimal criteria for participation of HTCs include access to reliable internet, human resources for data entry and commitment to long-term enrolment and follow-up of patients. The WBDR database is being developed through a collaboration between the WFH, Karolinska Institute and Health Solutions. By combining data from countries around the world, the WBDR will provide a large amount of real world data, on which researchers can address important scientific and clinical issues. The World Bleeding Disorders Registry (WBDR) is intended to fill existing gaps in knowledge by collecting real world data on the patient clinical experience around the globe.

Interventions

None listed

Sponsors

World Federation of Hemophilia
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
Number of participants recruited5 years
Number of participating Hemophilia Treatment Centres5 years
Number of participating countries5 years

Countries

Canada

Contacts

Primary ContactDonna Coffin, M.Sc.
dcoffin@wfh.org+15148757944
Backup ContactEmily Ayoub, Ph.D.
eayoub@wfh.org+15148757944

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026